TY - JOUR
T1 - Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site
AU - Kimura, A
AU - Tyacke, R J
AU - Robinson, J J
AU - Husbands, Stephen M
AU - Minchin, M C W
AU - Nutt, D J
AU - Hudson, A L
PY - 2009/7/7
Y1 - 2009/7/7
N2 - Drugs that bind to imidazoline binding proteins have major physiological actions. To date, three subtypes of such proteins, I-1, I-2 and I-3, have been proposed, although characterisations of these binding proteins are lacking. I-2 binding sites are found throughout the brain, particularly dense in the arcuate nucleus of the hypothalamus. Selective I-2 ligands demonstrate antidepressant-like activity and the identity of the proteins that respond to such ligands remained unknown until now. Here we report the isolation of a similar to 45 kDa imidazoline binding protein from rabbit and rat brain using a high affinity ligand for the I-2 subtype, 2-BFI, to generate an affinity column. Following protein sequencing of the isolated similar to 45 kDa imidazoline binding protein, we identified it to be brain creatine kinase (B-CK). B-CK shows high binding capacity to selective I-2 ligands; [H-3]-2-BFI (5 nM) specifically bound to B-CK (2330 +/- 815 fmol mg protein(-1)). We predicted an I-2 binding pocket near the active site of B-CK using molecular modelling. Furthermore, B-CK activity was inhibited by a selective I-2 irreversible ligand, where 20 mu M BU99006 reduced the enzyme activity by 16%, confirming the interaction between B-CK and the I-2 ligand. In summary, we have identified B-CK to be the similar to 45 kDa imidazoline binding protein and we have demonstrated the existence of an I-2 binding site within this enzyme. The importance of B-CK in regulating neuronal activity and neurotransmitter release may well explain the various actions of I-2 ligands in brain and the alterations in densities of I-2 binding sites in psychiatric disorders.
AB - Drugs that bind to imidazoline binding proteins have major physiological actions. To date, three subtypes of such proteins, I-1, I-2 and I-3, have been proposed, although characterisations of these binding proteins are lacking. I-2 binding sites are found throughout the brain, particularly dense in the arcuate nucleus of the hypothalamus. Selective I-2 ligands demonstrate antidepressant-like activity and the identity of the proteins that respond to such ligands remained unknown until now. Here we report the isolation of a similar to 45 kDa imidazoline binding protein from rabbit and rat brain using a high affinity ligand for the I-2 subtype, 2-BFI, to generate an affinity column. Following protein sequencing of the isolated similar to 45 kDa imidazoline binding protein, we identified it to be brain creatine kinase (B-CK). B-CK shows high binding capacity to selective I-2 ligands; [H-3]-2-BFI (5 nM) specifically bound to B-CK (2330 +/- 815 fmol mg protein(-1)). We predicted an I-2 binding pocket near the active site of B-CK using molecular modelling. Furthermore, B-CK activity was inhibited by a selective I-2 irreversible ligand, where 20 mu M BU99006 reduced the enzyme activity by 16%, confirming the interaction between B-CK and the I-2 ligand. In summary, we have identified B-CK to be the similar to 45 kDa imidazoline binding protein and we have demonstrated the existence of an I-2 binding site within this enzyme. The importance of B-CK in regulating neuronal activity and neurotransmitter release may well explain the various actions of I-2 ligands in brain and the alterations in densities of I-2 binding sites in psychiatric disorders.
KW - Imidazoline binding protein
KW - Harmane and psychiatric disorders
KW - Creatine kinase
KW - 2-BFI
UR - http://www.scopus.com/inward/record.url?scp=67649400330&partnerID=8YFLogxK
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722693/
UR - http://dx.doi.org/10.1016/j.brainres.2009.04.044
U2 - 10.1016/j.brainres.2009.04.044
DO - 10.1016/j.brainres.2009.04.044
M3 - Article
SN - 0006-8993
VL - 1279
SP - 21
EP - 28
JO - Brain Research
JF - Brain Research
ER -